Cancer Gene Therapy Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 21.10 Billion |
| Market Size (2029) | USD 97 Billion |
| CAGR (2024 - 2029) | 18.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cancer Gene Therapy Market Analysis
The Cancer Gene Therapy Market size is estimated at USD 21.10 billion in 2024, and is expected to reach USD 97 billion by 2029, growing at a CAGR of 18.30% during the forecast period (2024-2029).
Major factors driving the market are the rising prevalence and awareness of cancer, rising investments by public and private organizations in research and development activities for cancer gene therapeutics, and the increasing number of approvals by the US Food and Drug Administration approval for gene therapy drugs.
The rising prevalence of cancer cases is expected to drive the demand for novel cancer therapeutics, such as cancer gene therapy, which would drive the market over the forecast period. For instance, in February 2023, Cancer Research UK stated that the number of new cancer cases on average each year in the United Kingdom is projected to rise from around 420,000 cases in 2023-2025 to around 506,000 cases in 2038-2040. Thus, growing cancer cases across the world are expected to drive the demand for cancer gene therapy, driving the market over the forecast period.
The funding of research and development in cancer gene therapy has increased. For instance, in November 2023, AstraZeneca signed an investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next-generation therapeutics in areas of high unmet need of oncology. Under the terms of the partnership agreement, AstraZeneca will use Cellectis' proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy products for treating cancers. In addition, in September 2023, UK-based gene editing and modulation tech startup Pencil Biosciences raised around EUR 5.6 million (USD 6.2 million) in seed funding. According to the company, the investments will be used for the development of new gene therapeutic solutions for rare diseases and cancer.
Gene therapy products undergo rigorous regulatory scrutiny before they get approval. In cancer gene therapeutics, the mode of action will directly affect the genetic material of the tumor cells, which is highly selective and will have long-term effects compared to chemotherapy drugs. The number of approvals received for gene therapy products has increased due to the major advantage offered by these products over other treatments. The US FDA approved more than 10 products, including cancer gene therapeutics like Breyanzi (J uno Therapeutics Inc.) and KYMRIAH (Novartis AG) between 2021 and 2023. Additionally, many products under clinical trials are expected to receive final approval during the forecast period.
Thus, the rising prevalence of cancer cases, increasing investments in the development of cancer gene therapies, and increasing approval of cancer gene therapies by the FDA are expected to drive the market during the forecast period. However, the high cost involved in gene therapy and unwanted immune responses will likely restrain the growth of the market.
Cancer Gene Therapy Market Trends
The Gene Induced Immunotherapy Segment is Expected to Hold a Significant Share of the Market
Gene-induced immunotherapy is highly effective in some types of cancer caused by viruses. This therapy involves the insertion of a therapeutic gene to correct inappropriate gene products that cause cancer. T lymphocytes play a crucial role in the host's immune response to cancer. Modern gene-induced immunotherapies are, therefore, designed to induce or enhance T-cell reactivity against tumor antigens.
The increasing research activities for the development of new gene-induced immunotherapy and growing strategic activities, such as the launch of gene-induced immunotherapy products, primarily drive the segment.
The segment’s significant market share can be attributed to research studies that try to boost immunity to reduce the metastasis of tumor cells by selectively killing cancerous cells. Enhanced research activities in immunotherapy led to new US Food and Drug Administration (FDA) approvals. For instance, in January 2023, the FDA approved Adstiladrin, a gene immunotherapy drug developed by Ferring Pharmaceuticals that is indicated to treat unresponsive, non-muscle invasive bladder cancer. Hence, increasing research activities for the development of new cancer therapies are expected to drive the market over the forecast period.
Furthermore, increasing strategic activities, such as the launch of gene-induced immunotherapy drugs, are expected to drive the segment over the forecast period. For instance, in June 2024, Johnson and Johnson announced the US Food and Drug Administration approval for the CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. Hence, the launch of such products is expected to increase the accessibility of gene-induced immunotherapy drugs, ultimately driving the market over the forecast period.
Increasing research activities and FDA approvals of immunotherapy drugs are expected to boost the growth of the gene-induced immunotherapy segment over the forecast period.
North America is Expected to Dominate the Cancer Gene Therapy Market
The market in North America is expected to grow due to the rising prevalence of cancer cases, advancements in healthcare infrastructure, and increasing strategic activities by the key players.
The rising prevalence of cancer cases in North America is increasing the demand for novel therapeutics, such as cancer gene therapies; this is expected to drive market growth over the forecast period. For instance, according to the American Cancer Society 2024 update, about 2 million new cancer cases are expected to be diagnosed in the United States in 2024. Also, every day, around 5,480 cases of new cancer are likely to be identified in the United States. Thus, the high burden of cancer in the United States is expected to augment the demand for cancer gene therapies and drive the market over the forecast period.
As per the November 2023 update by the Canadian Cancer Society, about 239,100 Canadians were diagnosed with cancer in 2023. It also stated that 2 in 5 Canadians are expected to develop cancer in their lifetime. Thus, the high prevalence of cancer among the population necessitates the demand for novel therapeutics, such as gene therapies, fueling the market’s growth over the forecast period. Thus, the high burden of cancer is expected to augment the demand for cancer gene therapies and drive the market over the forecast period.
The high concentration of market players in the United States is another factor driving the growth of the market in the region. For instance, in August 2022, Merck & Co. Inc. partnered with Orna Therapeutics Inc. for the discovery, development, and commercialization of multiple programs, including the utilization of mRNA for cancer gene therapy. Hence, such strategic activities by key players are expected to drive the market over the forecast period.
Therefore, the rising prevalence of cancer cases and increasing strategic activities, such as the launch of new products, are expected to drive the market over the forecast period in North America.
Cancer Gene Therapy Industry Overview
The cancer gene therapy market is moderately consolidated and competitive due to the presence of many players. The market's major players are concentrating on joint ventures, strategic alliances, the introduction of new products, and geographic growth into developing and economically advantageous areas. Some of the major players include Bristol-Myers Squibb Company, Ferring BV, Janssen Biotech Inc., Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Kite Pharma Inc., Gilead Sciences Inc., Genulex Corporation, Amgen Inc., Merck & Co. Inc., CelgeneInc, and Adaptimmune Therapeutics PLC.
Cancer Gene Therapy Market Leaders
-
Novartis AG
-
Bristol-Myers Squibb Company
-
Gilead Sciences, Inc
-
Merck & Co
-
Amgen Inc.
*Disclaimer: Major Players sorted in no particular order
Cancer Gene Therapy Market News
- April 2024: Pfizer Inc., a biopharmaceutical company, reported that the US Food and Drug Administration (FDA) had approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B, who are on use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage.
- October 2023: Kite, a Gilead Company, and Epicrispr Biotechnologies entered a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies. The agreement will allow Kite to leverage the licensed technology to modulate certain genes to potentially enhance CAR T-cell functionality.
Cancer Gene Therapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence and Awareness of Cancer
4.2.2 Increasing Number of Approvals by the FDA for Gene Therapy Drugs
4.2.3 Rising Investments by Public and Private Organizations in Research and Development Activities for Cancer Gene Therapeutics
4.3 Market Restraints
4.3.1 High Cost of Cancer Gene Therapeutics
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Therapy
5.1.1 Gene Induced Immunotherapy
5.1.2 Oncolytic Virotherapy
5.1.3 Gene Transfer
5.2 By End User
5.2.1 Cancer Research Institutes
5.2.2 Diagnostic Centers
5.2.3 Others (Hospitals and biotechnology Companies)
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 Ferring BV
6.1.3 Janssen Biotech Inc.
6.1.4 Novartis AG
6.1.5 bluebird bio Inc.
6.1.6 Spark Therapeutics Inc.
6.1.7 Kite Pharma Inc.
6.1.8 Gilead Sciences Inc.
6.1.9 Genulex Corporation
6.1.10 Amgen Inc.
6.1.11 Merck & Co. Inc.
6.1.12 Celgene Inc.
6.1.13 Adaptimmune Therapeutics PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cancer Gene Therapy Industry Segmentation
Cancer gene therapy is a technique used for the treatment of cancer, where therapeutic DNA is introduced into the patient's gene. In the treatment, a functional gene, also known as therapeutic DNA, is inserted into the cells of a cancer patient to modify metabolism, alter or repair acquired genetic abnormalities, and impart new functions to cells.
The cancer gene therapy market is segmented by therapy, end user, and geography. By therapy, the market is segmented into gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. By end user, the market is segmented into cancer research institutes, diagnostic centers, and others (hospitals and biotechnology companies). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (USD) for all the above segments.
| By Therapy | |
| Gene Induced Immunotherapy | |
| Oncolytic Virotherapy | |
| Gene Transfer |
| By End User | |
| Cancer Research Institutes | |
| Diagnostic Centers | |
| Others (Hospitals and biotechnology Companies) |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cancer Gene Therapy Market Research FAQs
How big is the Cancer Gene Therapy Market?
The Cancer Gene Therapy Market size is expected to reach USD 21.10 billion in 2024 and grow at a CAGR of 18.30% to reach USD 97 billion by 2029.
What is the current Cancer Gene Therapy Market size?
In 2024, the Cancer Gene Therapy Market size is expected to reach USD 21.10 billion.
Who are the key players in Cancer Gene Therapy Market?
Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Merck & Co and Amgen Inc. are the major companies operating in the Cancer Gene Therapy Market.
Which is the fastest growing region in Cancer Gene Therapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cancer Gene Therapy Market?
In 2024, the North America accounts for the largest market share in Cancer Gene Therapy Market.
What years does this Cancer Gene Therapy Market cover, and what was the market size in 2023?
In 2023, the Cancer Gene Therapy Market size was estimated at USD 17.24 billion. The report covers the Cancer Gene Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cancer Gene Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cancer Gene Therapy Industry Report
Statistics for the 2024 Cancer Gene Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cancer Gene Therapy analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
